Jump Main Menu. Go directly to the main content

Sección de idiomas

EN

Fin de la sección de idiomas

Sección de utilidades

Calendar

Fin de la sección de utilidades

Events

Start of main content

New Therapies for the Inflammation Treatment

Life and Matter Sciences Session Feb 18th, 2025, Tuesday. 4PM Madrid

Información general:

Venue: Fundación Ramón Areces - salón de actos. Calle Vitruvio, 5. 28006. Madrid.

Free attendance until full capacity is reached. Prior online registration is required. Simultaneous interpretation.

The auditorium is equipped with a magnetic loop system.

Organized by:

Fundación Areces and the Chair of Solutex- University of Zaragoza

  • Description
  • Programme
  • Speaker/s
 

The science of inflammation resolution is an emerging field in biomedicine that focuses on understanding how the body actively regulates and terminates inflammatory processes. For years, it was believed that inflammation resolution was a passive process, but recent research has demonstrated that it is a precisely directed phenomenon driven by specialized biochemical mediators.

Among these mediators are the Specialized Proresolving Mediators (SPMs), a group of bioactive lipids that include resolvins, protectins, maresins, and lipoxins. These molecules are derived from essential fatty acids (mainly omega-3) and play a key role in promoting tissue repair, clearing damaged cells, and preventing chronic inflammation without compromising the immune response.

Dr. Charles Serhan, a leading researcher in this field, identified resolvins and other proresolving molecules in the early 2000s. His discoveries have transformed our understanding of inflammation, establishing that resolution is a biologically active process controlled by these mediators through endogenous enzymatic activity. This has opened new pathways for treating inflammatory and chronic diseases, such as osteoarthritis, cardiovascular diseases, and neurodegenerative disorders.

To date, over 2,000 articles have been published in indexed scientific journals addressing resolvins/SPMs and their role in biology and medicine. Additionally, several medications based on these concepts are currently in clinical development, highlighting their therapeutic potential.

In conclusion, the science of inflammation resolution offers an innovative approach to treating inflammatory conditions, emphasizing the importance of SPMs as natural regulators of health and immune balance.


"The Ramón Areces Foundation is not responsible for the opinions, comments or statements made by the people who participate in its activities".

Tuesday, 18 February

15:30 h.

Register of attendees

16:00 h.

Welcome and presentation

José María Medina
Vice President of the Fundación Areces Scientific Committee.

José Antonio Mayoral
Director of the Solutex Chair of Sustainable Chemistry and Rector of the University of Zaragoza.

16:10 h. 

Resolvins, and SPMs taught us about Inflammation & Infections

Charles Nicholas Serhan
Ph.D.,Dsc. MGB Harvard Medical.

17:10 h. 

Resolvins & SPMs in Pulmonary Medicine

Bruce David Levy
MD. MGB Harvard Medical.

17:50 h.

SPMs in Spinal Cord Injury

Jan Schwab
MD. Ohio, EE.UU. & Berlín, Germany.

18:30 h.

SPMs & the Resolution of Cancer Inflammation

Dipak Panigrahy
PMD. Boston BIDM - Harvard Universtity, EE.UU.

19:10 h. 

Q&A with closing remarks

Josep Vergés
Clinic pharmacologist and researcher specializing in osteoarthritis.

 

Charles Nicholas Serhan

Charles Serhan studies how the body resolves inflammation and repairs tissues. He discovered Specialized Pro-Resolving Mediators (SPMs) like resolvins, protectins, and maresins, derived from omega-3 fatty acids. These molecules stop excessive inflammation and promote healing without weakening the immune system. Serhan is also the President of the Scientific Committee at Solutex, a company specializing in lipid-based solutions. His research focuses on their mechanisms and potential treatments for chronic inflammatory diseases, opening new doors for therapies targeting inflammation resolution.

 

 
 

Bruce David Levy

Bruce David Levy, MD, investigates the mechanisms of lung inflammation and repair, focusing on diseases like asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS). His research explores specialized pro-resolving mediators (SPMs), which help resolve inflammation and promote tissue recovery. He studies how these mediators can be used to control excessive immune responses in the lungs. Levy's work aims to develop new therapies for lung diseases by enhancing natural resolution pathways. His findings contribute to better understanding and treatment of chronic and acute respiratory conditions.

 

Jan Schwab

Dr. Jan Schwab is a neurologist and physician-scientist specializing in spinal cord injury (SCI). His research focuses on understanding and treating maladaptive immune responses following SCI, including spinal cord injury-induced immune deficiency syndrome (SCI-IDS) and post-traumatic autoimmunity. These immune dysfunctions can lead to increased susceptibility to infections and hinder neurological recovery. Dr. Schwab's work aims to develop strategies to mitigate these adverse effects and improve patient outcomes.

 

Dipak Panigrahy

Dr. Dipak Panigrahy investigates the role of bioactive lipids in cancer biology, particularly how they influence tumor growth, metastasis, and angiogenesis. He studies lipid mediators like epoxyeicosatrienoic acids (EETs) and their effects on cancer progression. His research also examines how chemotherapy-induced cell debris triggers inflammation and cancer recurrence, aiming to improve treatment outcomes. Additionally, he explores the potential of Specialized Pro-Resolving

Mediators (SPMs) to promote tissue regeneration and inhibit tumor growth. Dr. Panigrahy’s work seeks to develop novel therapies that leverage these findings for cancer treatment.

 

 

Josep Vergés

Dr. Josep Vergés is a clinic pharmacologist and researcher specializing in osteoarthritis. He is the founder and president of the Osteoarthritis Foundation International (OAFI), established in 2016 in Barcelona, dedicated to the prevention and treatment of osteoarthritis and improving patients' quality of life. With over 35 years of experience in this field, Dr. Vergés has been instrumental in raising awareness about osteoarthritis and advocating for patient participation in health policies..

 

 

  • Activities related
  • Projects related
  • News related
  • Publications related

see all

End of main content